CorMedix Inc
NASDAQ: CRMD · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
CorMedix Inc (CRMD) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for CRMD.
Valued
Fundamentals support the current valuation. Strong combination of growth, quality, and price.
CRMD historical valuation range
Where current P/E sits in CRMD's own 5Y range.
CRMD intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
CRMD valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 3.94x
P/S Ratio — History
Current: 1.61x
Is CRMD overvalued in 2026?
CorMedix Inc (CRMD) currently trades at $7.51 per share with a market capitalization of $669,979,000.00. Based on our multi-factor framework, the stock looks attractively valued with a Smart Value Score of 80/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 3.9x, above its 5-year median of 3.8x.
Looking at its own history, CRMD is currently trading more expensive than 71% of the last 5Y on P/E. This places it in the 71th percentile of its historical range, a reasonable but unremarkable position.
A standard DCF model does not produce reliable output for CRMD under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: CRMD looks attractively valued on our framework, with a Smart Value Score of 80/100. The combination of reasonable price, healthy growth, and quality fundamentals makes it worth serious consideration.
Frequently asked questions
Is CRMD overvalued?
CRMD scores 80/100 on our Smart Value Score (Grade A), a strong overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is CRMD's fair value?
A standard DCF is unreliable for CRMD given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does CRMD trade at?
CRMD trades at a P/E of 3.9x on trailing twelve-month earnings, against a 5-year median of 3.8x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is CRMD a buy based on valuation?
Our Smart Value rating for CRMD is Strong Buy, from a Smart Value Score of 80/100 that blends growth, quality, and valuation. The rating leans on growth and financial strength, and valuation is usually the weakest leg for a name scoring this high. This is research to inform your decision, not personalized financial advice.
How does CRMD's valuation compare to its history?
On P/E, CRMD sits in the 71st percentile of its own 5Y range, above its long-run median relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is CRMD's Smart Value Score?
CRMD's Smart Value Score is 80/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.